论文部分内容阅读
生命科学子集团显著增长,材料科技子集团则低于预期水平●最近推出的处方药产品增长态势喜人——五个产品合并的年最高销售额预估值上调为75亿欧元以上●集团销售额达401.57亿欧元(增长1.0%;汇率与资产组合调整后:增长5.1%)●息税前利润增长25.6%,达49.34亿欧元●不计特殊项目的息税折旧摊销前利润增长1.5%,达84.01亿欧元●净收入增长32.7%,达31.89亿欧元●每股核心收益增长5.8%,达5.61欧元●2014年预测目标:销售额与收益进一步增长
Life sciences sub-group grows significantly and materials technology sub-group is lower than expected ● The recent launch of prescription drug products has seen a positive growth - the annualized sales forecast for the five products is raised to more than 7.5 billion euros ● Group sales up to 40.157 billion euros (up 1.0%; exchange rate and asset portfolio adjusted: up 5.1%) ● EBIT increased 25.6% to 4.934 billion euros ● EBITDA excluding special items increased 1.5% to 84.01 100 million euros ● Net income increased 32.7% to 3.189 billion euros ● Core earnings per share increased 5.8% to 5.61 euros ● 2014 forecast: Further growth in sales and revenue